This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delaney, W. E.
Right arrow Articles by Isom, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaney, W. E., IV
Right arrow Articles by Isom, H. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2017-2026, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of (-)-beta -2',3'-Dideoxy-3'-Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA

William E. Delaney IV,1,2 Thomas G. Miller,1 and Harriet C. Isom1,2,3,*

Department of Microbiology and Immunology,1 Cell and Molecular Biology Graduate Program,2 and Department of Pathology,3 Milton S. Hershey Medical Center, The Penn State University College of Medicine, Hershey, Pennsylvania 17033

Received 7 December 1998/Returned for modification 2 February 1999/Accepted 13 May 1999

(-)-beta -2',3'-Dideoxy-3'-thiacytidine (lamivudine [3TC]) is a nucleoside analog which effectively interferes with the replication of hepatitis B virus (HBV) DNA in vitro and in vivo. We have investigated the antiviral properties of 3TC in vitro in HepG2 cells infected with recombinant HBV baculovirus. Different types of information can be obtained with the HBV baculovirus-HepG2 system because (i) experiments can be carried out at various levels of HBV replication including levels significantly higher than those that can be obtained from conventional HBV-expressing cell lines, (ii) cultures can be manipulated and/or treated prior to or during the initiation of HBV expression, and (iii) high levels of HBV replication allow the rapid detection of HBV products including covalently closed circular (CCC) HBV DNA from low numbers of HepG2 cells. The treatment of HBV baculovirus-infected HepG2 cells with 3TC resulted in an inhibition of HBV replication, evidenced by reductions in the levels of both extracellular HBV DNA and intracellular replicative intermediates. The effect of 3TC on HBV replication was both dose and time dependent, and the reductions in extracellular HBV DNA that we observed agreed well with the previously reported efficacy of 3TC in vitro. As expected, levels of HBV transcripts and extracellular hepatitis B surface antigen and e antigen were not affected by 3TC. Importantly, the HBV baculovirus-HepG2 system made it possible to observe for the first time that CCC HBV DNA levels are lower in cells treated with 3TC than in control cells. We also observed that the treatment of HepG2 cells prior to HBV baculovirus infection resulted in a slight increase in the efficacy of 3TC compared to treatments starting 24 h postinfection. The treatment of HepG2 cells with the highest concentration of 3TC tested in this study (2 µM) prior to the initiation of HBV replication markedly inhibited the accumulation of CCC DNA, whereas treatment with the same concentration of 3TC at a time when CCC HBV DNA pools were established within the cells was considerably less effective. In addition, our results suggest that in HepG2 cells, non-protein-associated relaxed circular HBV DNA and particularly CCC HBV DNA are considerably more resistant to 3TC treatment than other forms of HBV DNA, including replicative intermediates and extracellular DNA. We conclude from these studies that the HBV baculovirus-HepG2 system has specific advantages for drug studies and can be used to complement other in vitro model systems currently used for testing antiviral compounds.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Milton S. Hershey Medical Center, The Penn State University College of Medicine, 500 University Dr., Hershey, PA 17033. Phone: (717) 531-8609. Fax: (717) 531-4133. E-mail: hisom{at}psu.edu.

Antimicrobial Agents and Chemotherapy, August 1999, p. 2017-2026, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Starkey, J. L., Chiari, E. F., Isom, H. C. (2009). Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J. Gen. Virol. 90: 115-126 [Abstract] [Full Text]  
  • Lucifora, J., Durantel, D., Belloni, L., Barraud, L., Villet, S., Vincent, I. E., Margeridon-Thermet, S., Hantz, O., Kay, A., Levrero, M., Zoulim, F. (2008). Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J. Gen. Virol. 89: 1819-1828 [Abstract] [Full Text]  
  • Gao, W., Hu, J. (2007). Formation of Hepatitis B Virus Covalently Closed Circular DNA: Removal of Genome-Linked Protein. J. Virol. 81: 6164-6174 [Abstract] [Full Text]  
  • Heipertz, R. A. Jr., Miller, T. G., Kelley, C. M., Delaney, W. E. IV, Locarnini, S. A., Isom, H. C. (2007). In Vitro Study of the Effects of Precore and Lamivudine-Resistant Mutations on Hepatitis B Virus Replication. J. Virol. 81: 3068-3076 [Abstract] [Full Text]  
  • Wang, R. Y.-L., Shen, C.-N., Lin, M.-H., Tosh, D., Shih, C. (2005). Hepatocyte-Like Cells Transdifferentiated from a Pancreatic Origin Can Support Replication of Hepatitis B Virus. J. Virol. 79: 13116-13128 [Abstract] [Full Text]  
  • Anderson, A. L., Banks, K. E., Pontoglio, M., Yaniv, M., McLachlan, A. (2005). Alpha/Beta Interferon Differentially Modulates the Clearance of Cytoplasmic Encapsidated Replication Intermediates and Nuclear Covalently Closed Circular Hepatitis B Virus (HBV) DNA from the Livers of Hepatocyte Nuclear Factor 1{alpha}-Null HBV Transgenic Mice. J. Virol. 79: 11045-11052 [Abstract] [Full Text]  
  • Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]  
  • Abdelhamed, A. M., Kelley, C. M., Miller, T. G., Furman, P. A., Cable, E. E., Isom, H. C. (2003). Comparison of Anti-Hepatitis B Virus Activities of Lamivudine and Clevudine by a Quantitative Assay. Antimicrob. Agents Chemother. 47: 324-336 [Abstract] [Full Text]  
  • Abdelhamed, A. M., Kelley, C. M., Miller, T. G., Furman, P. A., Isom, H. C. (2002). Rebound of Hepatitis B Virus Replication in HepG2 Cells after Cessation of Antiviral Treatment. J. Virol. 76: 8148-8160 [Abstract] [Full Text]  
  • Bilello, J. P., Delaney, W. E. IV, Boyce, F. M., Isom, H. C. (2001). Transient Disruption of Intercellular Junctions Enables Baculovirus Entry into Nondividing Hepatocytes. J. Virol. 75: 9857-9871 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T. G., Isom, H. C., Bock, C. T., Manns, M. P., Trautwein, C., Locarnini, S. (2001). Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 45: 1705-1713 [Abstract] [Full Text]  
  • Sprinzl, M. F., Oberwinkler, H., Schaller, H., Protzer, U. (2001). Transfer of Hepatitis B Virus Genome by Adenovirus Vectors into Cultured Cells and Mice: Crossing the Species Barrier. J. Virol. 75: 5108-5118 [Abstract] [Full Text]  
  • Whalley, S. A., Murray, J. M., Brown, D., Webster, G. J.M., Emery, V. C., Dusheiko, G. M., Perelson, A. S. (2001). Kinetics of Acute Hepatitis B Virus Infection in Humans. JEM 193: 847-854 [Abstract] [Full Text]  
  • Ren, S., Nassal, M. (2001). Hepatitis B Virus (HBV) Virion and Covalently Closed Circular DNA Formation in Primary Tupaia Hepatocytes and Human Hepatoma Cell Lines upon HBV Genome Transduction with Replication-Defective Adenovirus Vectors. J. Virol. 75: 1104-1116 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»